Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicaid | 17 | 2025 | 359 | 3.730 |
Why?
|
| Nursing Homes | 12 | 2024 | 671 | 3.010 |
Why?
|
| Accountable Care Organizations | 9 | 2025 | 67 | 2.670 |
Why?
|
| Atrial Fibrillation | 7 | 2024 | 831 | 2.480 |
Why?
|
| Anticoagulants | 8 | 2024 | 493 | 2.230 |
Why?
|
| Medicare | 11 | 2025 | 614 | 1.800 |
Why?
|
| Stroke | 5 | 2023 | 1184 | 1.510 |
Why?
|
| United States | 32 | 2025 | 7696 | 1.440 |
Why?
|
| Homes for the Aged | 2 | 2021 | 157 | 1.200 |
Why?
|
| Food Assistance | 2 | 2025 | 21 | 1.160 |
Why?
|
| Hospitalization | 7 | 2025 | 1338 | 1.100 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 717 | 1.080 |
Why?
|
| Memantine | 2 | 2024 | 23 | 1.060 |
Why?
|
| Hospice Care | 2 | 2025 | 65 | 1.010 |
Why?
|
| Patient-Centered Care | 3 | 2021 | 252 | 0.950 |
Why?
|
| Nutritional Support | 1 | 2025 | 12 | 0.950 |
Why?
|
| Cross-Sectional Studies | 14 | 2025 | 2529 | 0.950 |
Why?
|
| Aged | 22 | 2025 | 14203 | 0.920 |
Why?
|
| Hospices | 2 | 2025 | 35 | 0.880 |
Why?
|
| Skilled Nursing Facilities | 3 | 2023 | 83 | 0.880 |
Why?
|
| Potentially Inappropriate Medication List | 2 | 2021 | 14 | 0.860 |
Why?
|
| Dementia | 2 | 2024 | 257 | 0.850 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 37 | 0.840 |
Why?
|
| Inappropriate Prescribing | 2 | 2021 | 65 | 0.810 |
Why?
|
| Humans | 50 | 2025 | 62455 | 0.810 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 35 | 0.780 |
Why?
|
| Massachusetts | 10 | 2025 | 2061 | 0.760 |
Why?
|
| Emergency Service, Hospital | 4 | 2025 | 1064 | 0.750 |
Why?
|
| Warfarin | 2 | 2020 | 109 | 0.750 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 706 | 0.720 |
Why?
|
| Medicare Part C | 1 | 2021 | 13 | 0.710 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2022 | 120 | 0.700 |
Why?
|
| Administration, Oral | 4 | 2024 | 365 | 0.700 |
Why?
|
| Aged, 80 and over | 14 | 2025 | 5390 | 0.690 |
Why?
|
| Antipsychotic Agents | 4 | 2024 | 302 | 0.610 |
Why?
|
| Rivaroxaban | 1 | 2018 | 19 | 0.610 |
Why?
|
| Dabigatran | 1 | 2018 | 20 | 0.610 |
Why?
|
| Health Equity | 3 | 2025 | 45 | 0.610 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 294 | 0.600 |
Why?
|
| Italy | 6 | 2021 | 66 | 0.590 |
Why?
|
| Male | 25 | 2025 | 29366 | 0.580 |
Why?
|
| Brain Ischemia | 2 | 2019 | 417 | 0.580 |
Why?
|
| Metformin | 1 | 2019 | 73 | 0.570 |
Why?
|
| Female | 25 | 2025 | 32375 | 0.570 |
Why?
|
| Subacute Care | 1 | 2017 | 9 | 0.570 |
Why?
|
| Rehabilitation Centers | 1 | 2017 | 14 | 0.560 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 167 | 0.550 |
Why?
|
| Stroke Rehabilitation | 1 | 2017 | 50 | 0.530 |
Why?
|
| Ambulatory Care | 1 | 2019 | 310 | 0.530 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 214 | 0.530 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 476 | 0.490 |
Why?
|
| Cohort Studies | 5 | 2024 | 2530 | 0.490 |
Why?
|
| General Practitioners | 1 | 2015 | 15 | 0.480 |
Why?
|
| Hemorrhage | 3 | 2024 | 266 | 0.470 |
Why?
|
| Drug Utilization | 3 | 2021 | 210 | 0.460 |
Why?
|
| Nurses | 1 | 2015 | 104 | 0.440 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2024 | 47 | 0.430 |
Why?
|
| Health Care Costs | 3 | 2025 | 210 | 0.430 |
Why?
|
| Cost of Illness | 1 | 2014 | 161 | 0.420 |
Why?
|
| Retrospective Studies | 7 | 2024 | 6484 | 0.420 |
Why?
|
| Biopsy | 1 | 2014 | 429 | 0.400 |
Why?
|
| Proportional Hazards Models | 6 | 2022 | 724 | 0.400 |
Why?
|
| Managed Care Programs | 2 | 2025 | 89 | 0.400 |
Why?
|
| Patient Care Team | 1 | 2015 | 335 | 0.390 |
Why?
|
| Mammography | 1 | 2014 | 279 | 0.370 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5554 | 0.360 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 313 | 0.360 |
Why?
|
| Fee-for-Service Plans | 2 | 2021 | 70 | 0.350 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 583 | 0.350 |
Why?
|
| Primary Health Care | 3 | 2025 | 681 | 0.340 |
Why?
|
| Quality of Life | 1 | 2017 | 1216 | 0.340 |
Why?
|
| Middle Aged | 12 | 2025 | 17293 | 0.330 |
Why?
|
| Bipolar Disorder | 2 | 2022 | 246 | 0.320 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 549 | 0.310 |
Why?
|
| Mass Screening | 1 | 2014 | 686 | 0.300 |
Why?
|
| Cognition Disorders | 2 | 2021 | 220 | 0.290 |
Why?
|
| Sex Factors | 3 | 2021 | 968 | 0.280 |
Why?
|
| Medicare Part D | 2 | 2025 | 37 | 0.280 |
Why?
|
| Socioeconomic Factors | 3 | 2022 | 775 | 0.270 |
Why?
|
| Adult | 9 | 2025 | 16564 | 0.260 |
Why?
|
| Age Factors | 3 | 2021 | 1552 | 0.260 |
Why?
|
| Qualitative Research | 3 | 2025 | 667 | 0.250 |
Why?
|
| Child | 4 | 2025 | 4429 | 0.250 |
Why?
|
| Social Determinants of Health | 3 | 2022 | 128 | 0.240 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 1188 | 0.240 |
Why?
|
| Time Factors | 3 | 2019 | 3737 | 0.240 |
Why?
|
| Health Care Reform | 2 | 2023 | 87 | 0.240 |
Why?
|
| Diet Therapy | 1 | 2025 | 15 | 0.240 |
Why?
|
| Residence Characteristics | 3 | 2023 | 220 | 0.230 |
Why?
|
| Nurse Administrators | 1 | 2024 | 18 | 0.230 |
Why?
|
| Prescription Drugs | 1 | 2025 | 51 | 0.230 |
Why?
|
| Comparative Effectiveness Research | 1 | 2024 | 49 | 0.220 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 2638 | 0.220 |
Why?
|
| Prescriptions | 1 | 2023 | 33 | 0.210 |
Why?
|
| Deprescriptions | 1 | 2023 | 25 | 0.200 |
Why?
|
| Comorbidity | 3 | 2021 | 1117 | 0.200 |
Why?
|
| Social Responsibility | 1 | 2022 | 11 | 0.200 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 96 | 0.200 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1247 | 0.200 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 689 | 0.200 |
Why?
|
| Pediatrics | 1 | 2024 | 248 | 0.190 |
Why?
|
| Racism | 1 | 2023 | 87 | 0.190 |
Why?
|
| Chronic Disease | 1 | 2025 | 747 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 752 | 0.180 |
Why?
|
| Life Expectancy | 1 | 2021 | 34 | 0.180 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 65 | 0.180 |
Why?
|
| Drug Repositioning | 1 | 2021 | 6 | 0.180 |
Why?
|
| Risk Factors | 2 | 2023 | 5287 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 143 | 0.180 |
Why?
|
| Young Adult | 5 | 2025 | 4607 | 0.170 |
Why?
|
| Quality Indicators, Health Care | 2 | 2021 | 334 | 0.160 |
Why?
|
| Cognition | 1 | 2023 | 481 | 0.160 |
Why?
|
| Anticonvulsants | 1 | 2020 | 104 | 0.160 |
Why?
|
| Drug Substitution | 1 | 2019 | 42 | 0.160 |
Why?
|
| Geographic Mapping | 1 | 2018 | 8 | 0.150 |
Why?
|
| Epilepsy | 1 | 2020 | 110 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 339 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 168 | 0.150 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 64 | 0.150 |
Why?
|
| Thromboembolism | 1 | 2018 | 72 | 0.150 |
Why?
|
| Health Care Surveys | 1 | 2019 | 284 | 0.150 |
Why?
|
| Motivation | 1 | 2020 | 283 | 0.150 |
Why?
|
| Adolescent | 4 | 2025 | 6145 | 0.140 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 20 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2018 | 163 | 0.140 |
Why?
|
| Health Services Research | 1 | 2019 | 270 | 0.140 |
Why?
|
| Ischemic Attack, Transient | 1 | 2018 | 96 | 0.140 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 38 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2021 | 861 | 0.140 |
Why?
|
| Physicians | 1 | 2023 | 464 | 0.140 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 115 | 0.130 |
Why?
|
| Calcium Channel Blockers | 1 | 2017 | 60 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2017 | 153 | 0.130 |
Why?
|
| Disability Evaluation | 1 | 2017 | 211 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 59 | 0.120 |
Why?
|
| Salvage Therapy | 1 | 2015 | 73 | 0.120 |
Why?
|
| Physician-Nurse Relations | 1 | 2015 | 26 | 0.120 |
Why?
|
| Schizophrenia | 1 | 2017 | 267 | 0.120 |
Why?
|
| Medicine | 1 | 2015 | 58 | 0.120 |
Why?
|
| Pneumonia | 1 | 2017 | 286 | 0.120 |
Why?
|
| False Positive Reactions | 1 | 2014 | 78 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 133 | 0.110 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 253 | 0.110 |
Why?
|
| Length of Stay | 1 | 2017 | 797 | 0.110 |
Why?
|
| Insurance Coverage | 1 | 2014 | 100 | 0.110 |
Why?
|
| Mental Disorders | 1 | 2021 | 755 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2017 | 427 | 0.100 |
Why?
|
| Health Promotion | 1 | 2017 | 491 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 532 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2025 | 505 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 398 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 909 | 0.090 |
Why?
|
| Insurance Claim Review | 2 | 2022 | 76 | 0.080 |
Why?
|
| Pharmacists | 2 | 2023 | 124 | 0.080 |
Why?
|
| Quality of Health Care | 2 | 2023 | 516 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2024 | 196 | 0.050 |
Why?
|
| Health Policy | 1 | 2025 | 187 | 0.050 |
Why?
|
| Health Services Needs and Demand | 1 | 2024 | 207 | 0.050 |
Why?
|
| Housing | 1 | 2023 | 73 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 81 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2023 | 93 | 0.050 |
Why?
|
| Income | 1 | 2023 | 169 | 0.050 |
Why?
|
| Poverty | 1 | 2023 | 295 | 0.050 |
Why?
|
| Interinstitutional Relations | 1 | 2021 | 37 | 0.040 |
Why?
|
| Administrative Personnel | 1 | 2021 | 31 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2022 | 196 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2021 | 48 | 0.040 |
Why?
|
| Palliative Care | 1 | 2023 | 226 | 0.040 |
Why?
|
| Survival Rate | 1 | 2022 | 837 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 220 | 0.040 |
Why?
|
| Proteomics | 1 | 2021 | 283 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2023 | 433 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 568 | 0.040 |
Why?
|
| Senior Centers | 1 | 2017 | 1 | 0.040 |
Why?
|
| Genomics | 1 | 2021 | 357 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2021 | 355 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 572 | 0.040 |
Why?
|
| Injections | 1 | 2017 | 81 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 101 | 0.030 |
Why?
|
| Taiwan | 1 | 2017 | 10 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 299 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 869 | 0.030 |
Why?
|
| Health Resources | 1 | 2017 | 91 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 408 | 0.030 |
Why?
|
| Bias | 1 | 2017 | 112 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 416 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 154 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 160 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 661 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1343 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 860 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 928 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1359 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2017 | 358 | 0.030 |
Why?
|
| Vaccination | 1 | 2017 | 353 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2015 | 84 | 0.030 |
Why?
|
| Inpatients | 1 | 2017 | 300 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 716 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 851 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 1159 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2439 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2033 | 0.020 |
Why?
|